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 Abstract
Malignant peripheral sheath tumors (MPNST) are rare soft tissue sarcomas originating from peripheral 
sheath cells. The main risk factor is neurofibromatosis type 1 (NF-1). The localization in the head and neck 
region is uncommon (up to 15% of all cases of MPNST) making the diagnosis difficult due to anatomical 
and clinical reasons. We present a case of 45-years-old female with the NF-1- linked MPNST localized in 
the thyroid region with clinical manifestation as a left thyroid tumour. The patient underwent surgery and 
adjuvant radiation therapy, remaining disease-free for 14 months after the treatment. 
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 Streszczenie
Złośliwe nerwiaki osłonkowe (MPNST) należą do rzadko spotykanych mięsaków tkanek miękkich, wywo-
dzących się z komórek osłonek nerwów obwodowych. Najważniejszym czynnikiem ryzyka ich rozwoju 
jest nerwiakowłókniakowatość typu 1 — choroba Recklinghausena. Umiejscowienie tych nowotworów 
w regionie głowy i szyi zdarza się rzadko, a postawienie prawidłowego rozpoznania jest trudne z przyczyn 
anatomicznych i skrytego przebiegu klinicznego omawianych guzów. W pracy prezentujemy przypadek 
45-letniej kobiety z nerwiakowłókniakowatością typu 1 i złośliwym nerwiakiem osłonkowym umiejsco-
wionym w rzucie lewego płata tarczycy. Chora przebyła zabieg wycięcia guza z następczą radioterapią. 
W trakcie 14-miesięcznej obserwacji po leczeniu nie stwierdzono nawrotu choroby. 
Słowa kluczowe: złośliwy nerwiak osłonkowy, guzy głowy i szyi,  guzy tarczycy, nerwiakowłókniakowatość typu 1 (choroba 
von Recklinghausena), mięsaki tkanek miękkich
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Introduction
Malignant peripheral nerve sheath tumour (MPNST) is 
a rare malignancy originating from Schwann’s sheath of 
peripheral nerves. It usually arises from Schwann cells, 
but other cells of nerve sheath may also be the point of 
its origin including perineural fibroblasts or fibroblasts 
[1–6]. It may develop de novo or upon the base of prior-
ly existing neurofibroma. The main risk factor of this 
tumour is type 1 neurofibromatosis (von Recklinghau-
sen disease) — a  genetically backgrounded condition 




risk factors include previous irradiation (5–10% of cas-
es) [3, 7]. MPNSTs account for 5–10% of all soft tissue 
sarcomas in adult population with highest incidence in 
patients between 30 and 50 years of age, with no evident 
predominance of any gender[1, 8, 9]. About 30% of these 
tumours occur on the base of preexisting plexiform neu-
rofibroma and in this group of patients MPNST occurs 
one to two decades earlier. In the absence of preceding 
neurofibroma it is possible to see the conjunction of 
MPNST and a large peripheral nerve as the sciatic nerve, 
the brachial plexus or the sacral plexus. In rare cases 
multiple MPNSTs can arise in the setting of NF1 [2]. The 
head and neck occurrence is rare (about 8 to 16% of all 
MPNSTs) but particularly difficult in the treatment due 
to small anatomical space and adjacency of the tumour 
to vital structures [10]. Most of these tumours are high-
grade sarcomas with the potential to recur as well as to 
metastasize through the bloodstream. Nodal involvement 
is rare as in other soft tissue sarcomas. The main prog-
nostic factors for local recurrence or metastatic disease 
are: histologic grade, tumour size, tumour depth and 
presence of metastases at the time of diagnosis. Five- 
-years survival in most series remains at the level of 50%, 
being worse for patients with NF1 [1, 4, 6, 8]. Tumor size 
cutoff is 5 cm, with prognosis worsening precipitously in 
tumours over 5 cm in diameter. Wide local resection is still 
a mainstay in the treatment of MPNST [3, 6, 8]. Adjuvant 
radiation therapy showed its benefit in advanced cases 
(stage III and IV). Palliative radiation therapy is sometimes 
offered to the patients with inoperable or nonresectable 
tumours. There are very limited data concerning adjuvant 
chemotherapy in the treatment of MPNST, with no proven 
benefit in this disease. 
Preoperative diagnostics consists of thorough collec-
tion of patient’s history, physical examination, imaging 
(USG, CT/MRI), FNAB or tru-cut biopsy; open surgical 
biopsy is recommended in cases of doubtful or ambigu-
ous diagnosis [3, 11, 12].
The rare occurrence of the head and neck MPNSTs is 
reflected in available literature where mostly small series 
of cases or casual case reports can be found with only 
very few large-group or population-based analyses. This 
may lead to the misdiagnosis in patients with tumours 
located in some regions of the body, e.g. in close ad-
herence to thyroid gland. In such cases they can mimick 
primary thyroid malignancies thus resulting in suboptimal 
treatment and greater risk of non-radical resection. We 
publish our case report to add some information to our 
still poor knowledge of these uncommon malignancies.
Case report
45-years-old female was admitted to our centre for 
1 year history of gradually enlarging left thyroid lobe 
mass, hoarse voice and moderate dysphagia (Fig. 1). The 
past history showed autoimmunological thyroiditis with 
hypothyreosis and numerous small neurofibromas of the 
skin. Preoperative imaging (USG, contrast-enhanced CT) 
showed the multinodular goitre with large (7.5 × 7.4 × 
14.7 cm) dominant tumour of the left thyroid lobe with 
central necrosis, without infiltration of the blood vessels 
(Fig. 2). The left cervical lymph nodes were slightly en-
larged. No distant metastases were found. Fine needle 
biopsy showed malignant cells. The videostroboscopy 
showed the paresis of the left vocal chord with its inter-
mediate position without glottal stenosis (Fig. 3). 
The patient was included to the surgery with preopera-
tive diagnosis of thyroid cancer. Intraoperative inspection 
of the neck showed the well separated encapsulated 
tumour adjacent closely to the left thyroid lobe but not 
infiltrating it. The tumour mass seemed to emanate from 
the left vagus nerve and encased the internal jugular vein 
(Fig. 4). The tumour was dissected and removed together 
with regional lymph nodes of groups III, IV and V. The 
left common carotid artery and its bifurcation as well as 
internal jugular vein were cleaned of the malignant tis-
sue and the vagus nerve removed with the tumour. The 
thyroid gland was left intact (Fig. 5). The postoperative 
course was uncomplicated despite the permanent left 
vocal cord paresis. No signs of dysphagia or respiratory 
failure were found after the surgery. The drains were 
removed on the second and the skin suture on the fifth 
Figure 1. 45-years-old female with left cervical mass
Figure 2. CT imaging showed the left thyroid mass without 
infiltration of blood vessels
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Figure 3. Left vocal chord paresis shown in videostroboscopy
Figure 4. Well encapsulated tumour arising from parathyroid space Figure 5. Postoperative view of the tumour bed
postoperative day and the patient was discharged home 
on sixth postoperative day. 
The pathological report was as follows: Well delimi-
tated tumour with histological and immunohistochemical 
features of malignant nerve sheath tumour; six lymph 
nodes with no metastases; no thyroid tissue found in 
the specimen; immunohistochemistry: NSE, S100, PGP9, 
CD34 (++); Ki-67 — 15%. Since one margin of resection 
was doubtful the patient was operated four weeks later 
with the excision of the retrosternal remnant tissue. The 
tumour bed was marked with titanium clips for radiation 
therapy planning. The pathological report showed no 
malignant tissue in the excised specimen.
The patient underwent the adjuvant radiation therapy 
up to the dose of 45 Gy which was well-tolerated. Despite 
the permanent left vocal cord paresis no other complica-
tions of the treatment were found. 
The last follow-up within 14 months after the treat-
ment showed no recurrent disease. 
Discussion
MPNSTs are rare but highly aggressive soft tissue 
sarcomas, comprising 2–10% of all STSs [5, 6, 9, 11, 
13–15]. About 30 to 50% of all MPNST are associated with 
neurofibromatosis type 1 (von Recklinghausen disease) 
which is an autosomal dominantly inherited disorder with 
the frequency 1 per 3500 newborns [3, 6]. NF-1 associated 
MPNST occur 1–2 decades earlier than sporadic cases 
[16]. MPNSTs occur mostly in proximal extremities or in 
the trunk, the head and neck location being extremely 
rare As it was previously mentioned MPNST are generally 
uncommon tumours and the head and neck location is 
very rare — 8–16% of all MPNST [2, 5, 13, 14]. In this 
region they may develop in the nasal cavity, on the skull 
base or in the sinuses; parathyroid or parapharyngeal 
locations seem to be very uncommon. Most MPNSTs 
present as the rapidly growing mass, with or without 
pain; sometimes rhinorrhea or nasal stuffiness occur [1, 2, 
3, 13]. The tumours mimicking thyroid neoplasms were 
described only in several case reports. Their incidental 
occurrence may lead to the misdiagnosis and suboptimal 
treatment if they were considered to be typical thyroid 
cancers [2, 3]. 
The diagnosis is based upon contrast-enhanced — CT 
or MRI, followed by the fine-needle biopsy. In some cases 
FNAB may be non-diagnostic given that proper diagnosis 




sonography is a safe, easy and cost-effective modality but 
useful only in superficially located tumours [10]. PET-CT is 
a very sensitive in scanning the whole body for metasta-
ses but it lacks specificity. Contrast-enhanced computed 
tomography remains a  very useful imaging modality, 
especially for planning the surgery or irradiation. MRI is 
mostly recommended for diagnostics of MPNST, being 
a multi-parameter modality, providing information about 
different components of the tumour [4, 10]. 
Surgery remains the principle modality in the 
treatment of MPNST. Since the effective treatment of 
MPNSTs as well as other soft tissue sarcomas requiring 
wide surgical excision with free margins is difficult to be 
achieved in the head and neck region without significant 
morbidity. The anatomy of this part of the body often 
limitates the extent of surgery. The positive margins of 
resections are quite common in head and neck MPNST 
increasing the risk for local recurrence or spread of the 
disease [3, 13, 17]. 
The recommendation for adjuvant radiation therapy 
has been clearly established. Most authors advocate the 
postoperative radiation therapy in all cases of MPNST of 
the head and neck region, only few of them recommend 
this modality in cases with positive margins of resection 
[1, 2, 12, 13, 16]. The benefit of adjuvant radiation ther-
apy on overall survival and local recurrence has been 
confirmed, especially in patients with positive margins 
[1, 3, 11–13]. The dose of irradiation has also its impact 
on local control of the disease, eg. Wong et al. reported 
the 5-years local control as 73% for cumulative dose 
over 60 Gy (e.g. external beam, IORT and brachytherapy) 
versus 50% for lesser doses, but without the impact on 
survival [12].
Chemotherapy is mostly recommended in locally ad-
vanced, recurrent and metastatic cases [14]. Protocols 
are based upon doxorubicin and ifosfamide (Moretti) as 
a first-line treatment. Second-line chemotherapy remains 
poorly defined. The regimens consisted of gemcitabine/ 
/docetaxel or carboplatine/etoposide or ifosfamide/etopo-
side. Etoposide was introduced to the therapy upon the 
preclinical data of elevated topoisomerase II in MPNST. 
A phase II study with tyrosine kinase inhibitor — erlotinib 
— showed the lack of activity of this agent in MPNST [3, 4]. 
The results are inconsistent and the benefit of chemo-
therapy has not been statistically proven [1, 3, 11, 13, 14].
Overall survival in MPNST is still unsatisfactory. It 
still remains at the level of about 50%, with poorer prog-
nosis for NF-1 patients. The negative prognostic factors 
are also: tumour size > 5 cm in diameter, male gender, 
positive surgical resection and need for radiation therapy 
[4, 7, 11, 12, 14].
In our case the preoperative imaging pointed to the 
diagnosis of rapidly growing thyroid tumour. Even though 
the patient presented the clinical features of neurofibro-
matosis, she had not been previously diagnosed for this 
condition neither had she had any clinical surveillance. 
We ourselves also did not initially consider the link be-
tween her skin lesions and a tumour in the neck region. 
It was the first case of MPNST in our centre during last 
10 years and most of our thyroid surgeons did not even 
know about such a rare malignancy as MPNST. Consid-
ering the biopsy result the patient was operated with 
the preliminary diagnosis of thyroid cancer. Given that 
the surgery is the first-line treatment in thyroid cancer 
and that there is no neoadjuvant therapy in this kind of 
malignancy, the decision of surgical resection seemed 
to be quite obvious. Despite the fact that the tumour 
turned out to be a soft tissue sarcoma arising from the 
nerve sheath we do not find our decision as a wrong 
one. Neoadjuvant therapy in MPNST is not a standard 
option, mostly due to uncertain diagnosis in the biopsy. 
We resected the tumour as radically as possible with the 
addition of radiation therapy in the postoperative course. 
Given that the patient shows no recurrent disease after 
14 months after first operation we may hope that the 
treatment was successful. 
Generally, patients with neurofibromatosis type 1 are 
at particular risk of developing MPNST in comparison 
with general population, with a lifetime risk of MPNST of 
any location at about 6–10% [2, 3, 6, 13, 15]. Thus they 
should remain under clinical surveillance, especially if 
they present with plexiform neurofibromas. The estima-
tion of the risk of malignant transformation of plexiform 
neurofibroma to MPNST is difficult. There are some is-
sues concerning the diagnostics of loss of neurofibromin 
in NF-1 associated and sporadic MPNST. It was found 
that the loss of neurofibromin detected with the use of 
specific monoclonal antibodies occurs in almost 88% of 
NF-1 linked MPNST versus 43% in sporadic MPNST [7]. 
Neurofibromin specific antibody may also be used to 
differentiate MPNST from other spindle cell neoplasms 
[7]. The diagnostics and treatment of MPNST in different 
body sites are still unsatisfactory, with 5-years survival 
at about 50%. The schedule of postoperative follow-up 
has not been established due to rarity of the disease. No 
specific prevention is known. Since there are no specific 
imaging modalities allowing early diagnosis of MPNST in 
NF-1 patients the careful surveillance for any enlarging tu-
mour of any location may prevent those patients from the 
death from this aggressive and life-threatening malignan-
cy. As far as the head and neck MPNSTs are concerned 
it should be remembered that they can mimick different 
malignancies of this body part. Any rapidly enlarging 
mass of thyroid region should always undergo a differ-
ential diagnosis between an aggressive thyroid cancer 
and other malignancies like MPNSTs or lymphomas in 
order to avoid misdiagnosis and suboptimal treatment. 
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